Cargando…
Glioblastoma and Increased Survival with Longer Chemotherapy Duration
INTRODUCTION: The five-year survival rate for patients with glioblastoma (GBM) is low at approximately 4.7%. Radiotherapy plus concomitant and adjuvant temozolomide (TMZ) remains the standard of care. The optimal duration of therapy with TMZ is unknown. This study sought to evaluate the survival ben...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
University of Kansas Medical Center
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710024/ https://www.ncbi.nlm.nih.gov/pubmed/31489102 |
_version_ | 1783446278712066048 |
---|---|
author | Jaoude, Dory Abou Moore, Joseph A. Moore, Matthew B. Twumasi-Ankrah, Philip Ablah, Elizabeth Moore, Dennis F. |
author_facet | Jaoude, Dory Abou Moore, Joseph A. Moore, Matthew B. Twumasi-Ankrah, Philip Ablah, Elizabeth Moore, Dennis F. |
author_sort | Jaoude, Dory Abou |
collection | PubMed |
description | INTRODUCTION: The five-year survival rate for patients with glioblastoma (GBM) is low at approximately 4.7%. Radiotherapy plus concomitant and adjuvant temozolomide (TMZ) remains the standard of care. The optimal duration of therapy with TMZ is unknown. This study sought to evaluate the survival benefit of two years of treatment. METHODS: This was a retrospective chart review of all patients diagnosed with GBM and treated with TMZ for up to two years between January 1, 2002 and December 31, 2011. The Kaplan-Meier method with log-rank test was used to estimate the progression-free survival (PFS) and the overall survival (OS). The results were compared to historical controls and data from previous clinical trials of patients treated up to one year. RESULTS: Data from 56 patients with confirmed GBM were evaluated. The OS probability was 54% (SE = 0.068) at one year, 28.3% (SE = 0.064) at two years, 17.8% (SE = 0.059) at three years, and 4% (SE = 0.041) at five years. Seven patients (12.5%) were treated with TMZ for two years. Their median time-to-progression was 28 months (95% CI = 5.0 – 28.0), and they had an increased survival probability at three years compared to other patients (log-rank test χ(2) (1, N = 56) = 19.2, p < 0.0001). CONCLUSIONS: There may be an advantage for a longer duration of TMZ therapy among patients with GBM, but the sample size was too small for generalization. A multicenter prospective study is needed to identify optimal duration of TMZ therapy. |
format | Online Article Text |
id | pubmed-6710024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | University of Kansas Medical Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-67100242019-09-05 Glioblastoma and Increased Survival with Longer Chemotherapy Duration Jaoude, Dory Abou Moore, Joseph A. Moore, Matthew B. Twumasi-Ankrah, Philip Ablah, Elizabeth Moore, Dennis F. Kans J Med Original Research INTRODUCTION: The five-year survival rate for patients with glioblastoma (GBM) is low at approximately 4.7%. Radiotherapy plus concomitant and adjuvant temozolomide (TMZ) remains the standard of care. The optimal duration of therapy with TMZ is unknown. This study sought to evaluate the survival benefit of two years of treatment. METHODS: This was a retrospective chart review of all patients diagnosed with GBM and treated with TMZ for up to two years between January 1, 2002 and December 31, 2011. The Kaplan-Meier method with log-rank test was used to estimate the progression-free survival (PFS) and the overall survival (OS). The results were compared to historical controls and data from previous clinical trials of patients treated up to one year. RESULTS: Data from 56 patients with confirmed GBM were evaluated. The OS probability was 54% (SE = 0.068) at one year, 28.3% (SE = 0.064) at two years, 17.8% (SE = 0.059) at three years, and 4% (SE = 0.041) at five years. Seven patients (12.5%) were treated with TMZ for two years. Their median time-to-progression was 28 months (95% CI = 5.0 – 28.0), and they had an increased survival probability at three years compared to other patients (log-rank test χ(2) (1, N = 56) = 19.2, p < 0.0001). CONCLUSIONS: There may be an advantage for a longer duration of TMZ therapy among patients with GBM, but the sample size was too small for generalization. A multicenter prospective study is needed to identify optimal duration of TMZ therapy. University of Kansas Medical Center 2019-08-21 /pmc/articles/PMC6710024/ /pubmed/31489102 Text en © 2019 The University of Kansas Medical Center This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Original Research Jaoude, Dory Abou Moore, Joseph A. Moore, Matthew B. Twumasi-Ankrah, Philip Ablah, Elizabeth Moore, Dennis F. Glioblastoma and Increased Survival with Longer Chemotherapy Duration |
title | Glioblastoma and Increased Survival with Longer Chemotherapy Duration |
title_full | Glioblastoma and Increased Survival with Longer Chemotherapy Duration |
title_fullStr | Glioblastoma and Increased Survival with Longer Chemotherapy Duration |
title_full_unstemmed | Glioblastoma and Increased Survival with Longer Chemotherapy Duration |
title_short | Glioblastoma and Increased Survival with Longer Chemotherapy Duration |
title_sort | glioblastoma and increased survival with longer chemotherapy duration |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710024/ https://www.ncbi.nlm.nih.gov/pubmed/31489102 |
work_keys_str_mv | AT jaoudedoryabou glioblastomaandincreasedsurvivalwithlongerchemotherapyduration AT moorejosepha glioblastomaandincreasedsurvivalwithlongerchemotherapyduration AT moorematthewb glioblastomaandincreasedsurvivalwithlongerchemotherapyduration AT twumasiankrahphilip glioblastomaandincreasedsurvivalwithlongerchemotherapyduration AT ablahelizabeth glioblastomaandincreasedsurvivalwithlongerchemotherapyduration AT mooredennisf glioblastomaandincreasedsurvivalwithlongerchemotherapyduration |